Search

Your search keyword '"Lahutte, Marion"' showing total 23 results
Start Over Author "Lahutte, Marion"
23 results on '"Lahutte, Marion"'

1. New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study

Author

Bompaire, Flavie, Lahutte, Marion, Buffat, Stephane, Soussain, Carole, Ardisson, Anne Emmanuelle, Terziev, Robert, Sallansonnet-Froment, Magali, De Greslan, Thierry, Edmond, Sébastien, Saad, Mehdi, Nioche, Christophe, Durand, Thomas, Alamowitch, Sonia, Xuan, Khe Hoang, Delattre, Jean Yves, Renard, Jean Luc, Taillia, Hervé, Chargari, Cyrus, Psimaras, Dimitri, and Ricard, Damien

Published
2018
Full Text
View/download PDF

11. Mésentère commun

Author

Moritz, Celine, primary, Lahutte, Marion, additional, Malgras, Brice, additional, and Ezanno, Anne-Cécile, additional

Published
2020
Full Text
View/download PDF

15. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression

Author

Reyes-Botero, German, primary, Dehais, Caroline, additional, Idbaih, Ahmed, additional, Martin-Duverneuil, Nadine, additional, Lahutte, Marion, additional, Carpentier, Catherine, additional, Letouzé, Eric, additional, Chinot, Olivier, additional, Loiseau, Hugues, additional, Honnorat, Jerome, additional, Ramirez, Carole, additional, Moyal, Elisabeth, additional, Figarella-Branger, Dominique, additional, Ducray, François, additional, Desenclos, Christine, additional, Sevestre, Henri, additional, Menei, Philippe, additional, Michalak, Sophie, additional, Al Nader, Edmond, additional, Godard, Joel, additional, Viennet, Gabriel, additional, Carpentier, Antoine, additional, Eimer, Sandrine, additional, Dam-Hieu, Phong, additional, Quintin-Roué, Isabelle, additional, Guillamo, Jean-Sebastien, additional, Lechapt-Zalcman, Emmanuelle, additional, Kemeny, Jean-Louis, additional, Verrelle, Pierre, additional, Faillot, Thierry, additional, Gaultier, Claude, additional, Tortel, Marie Christine, additional, Christov, Christo, additional, Le Guerinel, Caroline, additional, Aubriot-Lorton, Marie-Hélène, additional, Ghiringhelli, Francois, additional, Berger, François, additional, Lacroix, Catherine, additional, Parker, Fabrice, additional, Dubois, François, additional, Maurage, Claude-Alain, additional, Gueye, Edouard-Marcel, additional, Labrousse, Francois, additional, Jouvet, Anne, additional, Bauchet, Luc, additional, Rigau, Valérie, additional, Beauchesne, Patrick, additional, Vignaud, Jean-Michel, additional, Campone, Mario, additional, Loussouarn, Delphine, additional, Fontaine, Denys, additional, Vandenbos, Fanny, additional, Campello, Chantal, additional, Roger, Pascal, additional, Fesneau, Melanie, additional, Heitzmann, Anne, additional, Delattre, Jean-Yves, additional, Elouadhani, Selma, additional, Mokhtari, Karima, additional, Polivka, Marc, additional, Ricard, Damien, additional, Levillain, Pierre-Marie, additional, Wager, Michel, additional, Colin, Philippe, additional, Diebold, Marie-Danièle, additional, Chiforeanu, Dan, additional, Vauleon, Elodie, additional, Langlois, Olivier, additional, Laquerriere, Annie, additional, Motsuo Fotso, Marie Janette, additional, Peoc'h, Michel, additional, Andraud, Marie, additional, Mouton, Servane, additional, Chenard, Marie-Pierre, additional, Noel, Georges, additional, Desse, Nicolas, additional, Soulard, Raoulin, additional, Amiel-Benouaich, Alexandra, additional, Uro-Coste, Emmanuelle, additional, and Dhermain, Frederic, additional

Published
2013
Full Text
View/download PDF

23. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

Author

Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, and Delattre JY

Subjects
Adult, Aged, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab, Brain Neoplasms diagnosis, Brain Neoplasms drug therapy, Brain Neoplasms mortality, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Disease Progression, Female, Glioblastoma drug therapy, Humans, Irinotecan, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local drug therapy, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Diagnostic Imaging standards, Glioblastoma diagnosis, Glioblastoma mortality, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local mortality, Outcome Assessment, Health Care standards
Abstract

Traditionally, the most widely used criteria for response assessment in glioblastoma have been Macdonald and the Response Evaluation Criteria In Solid Tumors (RECIST). Recently, new criteria addressing contrast enhancement and fluid-attenuated inversion recovery (FLAIR)/T2 hyperintensity have been defined (the Response Assessment in Neuro-Oncology criteria) to better evaluate the effect of antiangiogenic therapy. Whether FLAIR/T2 imaging could also be helpful to refine RECIST criteria remains unresolved. This study proposed the RECIST + F criteria and compared the 4 methods (Macdonald, RECIST, RANO, and RECIST + F) to determine their agreement in identifying response and progression of recurrent glioblastomas to irinotecan-bevacizumab. Patients with recurrent glioblastoma treated with second-line irinotecan-bevacizumab were eligible. Clinical status, corticosteroid dose, and 1-dimensional and 2-dimensional measurements of tumor contrast enhancement and FLAIR hyperintensity were retrospectively assessed. Response and progression were determined according to each set of criteria. Seventy-eight patients were included. Response rates ranged from 34.2% with RECIST + F to 44.7% with Macdonald criteria. Agreement among the 4 methods in determining response and type of progression was high (kappa statistic > 0.75). One-third of patients exhibited nonenhancing progression with stable or improved contrast enhancement. Median progression-free survival was predicted by RECIST, at 13.6 weeks; RECIST + F, 12.3; Macdonald, 12.7; and RANO, 11.7 (P = .840). Intra- and interobserver correlations were high for both contrast enhancement and FLAIR hyperintensity measurements. There was a strong concordance among the different methods in determining response and progression to irinotecan-bevacizumab. Criteria integrating FLAIR hyperintensity tended, however, to reduce response rates and progression-free survival compared with criteria considering only contrast enhancement. The 1-dimensional approach appeared to be as valid as the 2-dimensional approach.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results